Biotechnology
Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
Promising anti-tumor activity reported for C-CAR031, a novel Glypican 3 (GPC3)-targeting cell therapy designed by AstraZeneca SHANGHAI, April 18, 2023 /PRNewswire/ -- Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development...
2023-04-18 04:15
1718
EXCHANGE OFFER DECLARED UNCONDITIONAL
KAISERAUGST, Switzerland, HEERLEN, Netherlands and GENEVA, April 18, 2023 /PRNewswire/ -- THIS PRESS RELEASE IS NOT FOR GENERAL RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY,THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATIO...
2023-04-18 01:51
1905
Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting
* Five posters showcased progress with multiple preclinical and clinical programs, includingATG-008 (mTORC1/2 inhibitor), ATG-017 (ERK1/2 inhibitor), ATG-037 (CD73 inhibitor), ATG-031 (anti-CD24 monoclonal antibody) and ATG-034 (LILRB4 antagonist antibody) * Clinical results showed promising ...
2023-04-17 20:22
2009
Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023
SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AACR Annual Meeting 2023 (AACR 2023). The AACR Annual Meet...
2023-04-17 14:01
1858
EBMI INKED MOA WITH SFIO TO BUILD A WORLD-CLASSS INTEGRATIVE CARE FACILITY IN PALAWAN, PHILIPPINES
MANILA, Philippines, April 17, 2023 /PRNewswire/ -- European Biological Medicine Inc., a subsidiary of European Wellness Biomedical Group (EW Group) has inked a Memorandum of Agreement (MoA) with Starfleet Innotech, Inc. (SFIO) to build a world-class integrative care facility in Palawan,Philippin...
2023-04-17 11:00
2528
AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
SHANGHAI, April 17, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychi...
2023-04-17 09:00
4206
Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-17 08:33
3097
Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged
SHANGHAI, April 17, 2023 /PRNewswire/ -- As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched inChina. Leveraging the differentiated competitive edges of its pr...
2023-04-17 07:45
2040
Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark
BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European...
2023-04-17 07:00
2125
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) ...
2023-04-17 06:38
1730
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering
SINGAPORE, April 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company"), a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers, today announced ...
2023-04-14 08:00
4101
Menarini Silicon Biosystems new CELLSEARCH® data presented at AACR 2023 annual meeting highlights trailblazing contributions of liquid biopsies for cancer research
Menarini Silicon Biosystems continues to support advances in cancer research by developing new tools and solutions to automate the identification of CELLSEARCH® CTCs (Circulating Tumor Cells) through AI (Artificial Intelligence) and expand the use of liquid biopsies through the analysis of mu...
2023-04-13 20:36
1823
EW GROUP SHINES AT 12TH A4M SYMPOSIUM 2023 & "ALL-ON BIOREGEN OPTIMIZATION" WORKSHOP
BANGKOK, April 13, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) made a successful showing at an exclusive event, the 12th A4M Symposium 2023, which was held in Centara,Bangkok, 16th-19th February 2023. The two-day A4M Symposium, commenced with a welcome ceremony featuring ...
2023-04-13 12:20
2468
Altair to Showcase Pharmaceutical Process Optimization Technology at the Korea Pharm&Bio 2023
Altair will feature pharmaceutical manufacturing process simulation and data analytics technologies SEONGNAM, South Korea, April 13, 2023 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI), will be exhibiting at Korea Pharm&Bio,April ...
2023-04-13 08:00
2934
TÜV Rheinland Headquarters Receives Kingfa Delegation
COLOGNE, Germany, April 12, 2023 /PRNewswire/ -- Recently, the international independent third-party testing, inspection, and certification organization TÜV Rheinland Group received a delegation from Kingfa Sci. & Tech. Co., Ltd. The delegation included LI Nanjing, the CEO and Co-founder, DING...
2023-04-12 17:34
2595
DISCOVERY LIFE SCIENCES ACQUIRES REACHBIO RESEARCH LABS
Acquisition to enhance cell biology capabilities and accelerate assessments of potential new drug targets HUNTSVILLE, Ala., April 11, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, has acquired Seattle -basedReachBio Research Labs (ReachBio...
2023-04-11 21:05
2613
Inotiv Applauded by Frost & Sullivan as Key Competitor in the Bio-analytical Testing Services Market
Inotiv offers fit-for-purpose drug testing approaches and quality-by-design methodologies to facilitate sample analysis accuracy, boosting clients' success rates. SAN ANTONIO, April 11, 2023 /PRNewswire/ -- Recently, Frost & Sullivan assessed the bio-analytical testing services industry and, bas...
2023-04-11 21:00
3177
Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil
YANTAI, China, April 11, 2023 /PRNewswire/ -- Boan Biotech today announced that Brazil's Agência Nacional de Vigilância Sanitária (ANVISA) has accepted the company's Biologics License Application (BLA) for Boyounuo® (Bevacizumab Injection). Envisioned to be "a leading global biopharmaceutical co...
2023-04-11 20:19
2676
ACM Biolabs Further Strengthens Leadership, Appoints David Lawrence to Board of Directors
SINGAPORE, April 11, 2023 /PRNewswire/ -- ACM Biolabs (FR0012596468 – ALSEN) a pioneering Singaporean-Swiss biotechnology company, which specializes in the development of targeted therapeutics for the prevention of multiple life-threatening diseases based on its proprietary ACM (Artificial Cell ...
2023-04-11 19:00
1883
Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma
GUANGZHOU, China, April 11, 2023 /PRNewswire/ -- April 7th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted IND approval by China NMPA for the company's first-in-class T-cell redirection therapy, it is an autologous T cell therapy for EBV-positive lymphoma. The principle of autol...
2023-04-11 18:09
2159
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 292 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 254 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 250 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2937
